Profile data is unavailable for this security.
About the company
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
- Revenue in USD (TTM)5.16m
- Net income in USD-17.89m
- Incorporated2006
- Employees11.00
- LocationKineta Inc7683 Se 27Th Street, Suite 481MERCER ISLAND 98040United StatesUSA
- Phone+1 (206) 378-0400
- Fax+1 (302) 636-5454
- Websitehttps://kinetabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ainos Inc | 93.68k | -14.56m | 5.40m | 46.00 | -- | 0.233 | -- | 57.69 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
HST Global Inc | 0.00 | -146.22k | 5.46m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
NLS Pharmaceutics AG | 0.00 | -12.17m | 5.58m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
Synaptogenix Inc | 0.00 | -12.23m | 5.61m | 5.00 | -- | 0.2239 | -- | -- | -37.38 | -37.38 | 0.00 | 21.08 | 0.00 | -- | -- | 0.00 | -13.75 | -40.33 | -15.54 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
Clever Leaves Holdings Inc | 17.42m | -19.80m | 5.62m | 296.00 | -- | 0.2283 | -- | 0.3224 | -12.57 | -11.38 | 11.11 | 14.02 | 0.418 | 1.69 | 11.03 | 58,841.21 | -47.51 | -23.20 | -58.14 | -26.55 | 37.64 | -- | -113.66 | -207.52 | 1.63 | -3.70 | 0.0479 | -- | 6.14 | -- | 47.63 | -- | -- | -- |
Burzynski Research Institute Inc | 0.00 | -1.19m | 5.65m | 2.00 | -- | -- | -- | -- | -0.009 | -0.009 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -84,895.00 | -10,098.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.18 | -- | -- | -- |
Kineta Inc | 5.16m | -17.89m | 5.69m | 11.00 | -- | -- | -- | 1.10 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
Pasithea Therapeutics Corp | 0.00 | -16.10m | 5.70m | 8.00 | -- | 0.2865 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
Hoth Therapeutics Inc | 0.00 | -7.70m | 5.72m | 2.00 | -- | 0.6578 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
Glucose Health Inc | 1.11m | -456.46k | 5.80m | 2.00 | -- | 6.12 | -- | 5.21 | -0.033 | -0.033 | 0.0803 | 0.0561 | -- | -- | -- | -- | -- | -86.94 | -- | -153.95 | 47.19 | 40.68 | -31.99 | -56.93 | 313.11 | -- | 0.00 | -- | 98.39 | 24.94 | 16.87 | -- | -- | -- |
AiXin Life International Inc | 4.09m | -2.09m | 5.82m | 207.00 | -- | -- | -- | 1.42 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
Silo Pharma Inc | 72.12k | -3.53m | 5.83m | 3.00 | -- | 1.11 | -- | 80.85 | -1.18 | -1.20 | 0.024 | 1.87 | 0.008 | -- | -- | 24,040.00 | -39.26 | -24.90 | -43.11 | -26.39 | 91.90 | 82.79 | -4,889.57 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
Protagenic Therapeutics Inc | 0.00 | -6.01m | 5.85m | -- | -- | 2.75 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | -- | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
Creative Medical Technology Holdings Inc | 9.00k | -5.28m | 5.86m | 4.00 | -- | 0.6385 | -- | 651.59 | -3.74 | -3.74 | 0.0064 | 6.81 | 0.0007 | 0.4291 | -- | 2,250.00 | -42.47 | -110.00 | -43.88 | -- | 60.00 | 65.82 | -58,624.33 | -7,961.14 | 23.53 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
Titan Pharmaceuticals Inc | 87.00k | -4.95m | 5.95m | 4.00 | -- | 0.978 | -- | 68.41 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
Virios Therapeutics Inc | 0.00 | -5.07m | 5.97m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Mar 2024 | 1.05m | 9.54% |
The Colony Group LLCas of 31 Mar 2024 | 92.40k | 0.84% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 59.33k | 0.54% |
Geode Capital Management LLCas of 31 Mar 2024 | 50.03k | 0.46% |
Citadel Securities LLCas of 31 Mar 2024 | 30.07k | 0.27% |
Millennium Management LLCas of 31 Mar 2024 | 29.24k | 0.27% |
Jane Street Capital LLCas of 31 Mar 2024 | 28.95k | 0.26% |
Two Sigma Securities LLCas of 31 Mar 2024 | 27.65k | 0.25% |
Evergreen Capital Management LLCas of 31 Mar 2024 | 20.85k | 0.19% |
Brighton Jones LLCas of 31 Mar 2024 | 20.65k | 0.19% |